dm+d

445499001

Refrigerated Storage

VPRIVShire Pharmaceuticals

Shire Pharmaceuticals
VPRIV
400 units powder for solution for infusion

Takeda (now part of Shire) has conducted internal stability studies to evaluate the impact of temperature excursions on velaglucerase alfa vials (Shire Internal Data). Results indicate there is no impact on the product stability or original shelf life of velaglucerase alfa during a single temperature excursion of:

Temperature Limits Maximum Duration
-20°C to <2°C 6 days
>8°C to ≤27°C 15 days
>27°C to ≤40°C 2 days

 

This is subject to the product being stored at the licensed storage conditions for the remaining period of time. These studies suggested that the quality attributes of the product would be expected to be maintained until expiration date. Please note, stability data at Shire is continually monitored and subject to change. Please contact Shire on a case by case basis for any temperature excursions.

Contact Shire in all cases where deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details. Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

No - when exposed to the temperatures stated above
Yes
19 November 2020
London Medicines Information Service